XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Stock Information for Turnstone Biologics Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Turnstone Biologics Corp.

Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
ESSA Pharma Inc. Amends Agreement with XenoTherapeutics
XOMA Royalty Declares Quarterly Preferred Stock Dividends

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.